Competition in the market for KIT inhibitors is fierce, with key industry players including ONO Pharmaceutical and Blueprint Medicines leading the way. Meanwhile, Celldex Therapeutics, Cogent Biosciences, and Blueprint Medicines are making significant strides in the sector. The market is marked by intense rivalry, with a focus on innovation and market positioning.